Form 4 Filing for Apogee Therapeutics, Inc.

This filing details insider transactions for Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. On April 1, 2026, Dambkowski acquired 4,125 shares of Common Stock through the exercise of a stock option at a price of $22.86 per share. Concurrently, he disposed of 2,698 shares at a weighted average price of $84.31, another 2,702 shares at a weighted average price of $85.33, and 100 shares at $85.89. These disposals were executed under a Rule 10b5-1 trading plan. Following these transactions, Dambkowski holds 208,398 shares of Common Stock directly and has 127,165 stock options remaining.